Active-ingredient Dossier

Aflibercept

Active-ingredient Dossier for Aflibercept (vascular endothelial growth factor inhibitor). Australian brands, products, PBS listings, PBAC outcomes —…

Brand: AFQLIR
Brand: EYLEA
Brand: EYDENZELT
Brand: OPUVIZ
Brand: ENZEEVU
Therapeutic area: Ophthalmology

What is

Aflibercept Aflibercept is a vascular endothelial growth factor inhibitor.

Australian brands containing

Aflibercept — AFQLIR — EYLEA — EYDENZELT — OPUVIZ — ENZEEVU

Therapeutic areas

Aflibercept is registered in ophthalmology, with 5 brands containing the ingredient.

Sponsor landscape

Aflibercept is marketed by four sponsors: Sandoz, Celltrion Healthcare, Bayer, and Samsung Bioepis AU.

PBS and regulatory activity

Two brands containing aflibercept have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In fiscal year 2024–25, government expenditure on aflibercept reached $464.0 million across 472,372 scripts. Three brands have PBAC outcomes on record, with the latest PBAC decision from 1 November 2025. Five brands have AusPARs on record, with the latest issued on 10 September 2025.